Jacobs Levy Equity Management, Inc Beam Therapeutics Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 43,199 shares of BEAM stock, worth $766,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,199Holding current value
$766,782% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
258Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$176 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$157 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$151 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$136 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$80.6 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.25B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...